Using AI to diagnose and treat diseases in older adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to collect and analyze various characteristics such as handwriting, gait, speech, eye movements, and biological samples from patients with Parkinson's disease, Alzheimer's disease, and other neurological disorders, as well as healthy elderly and young controls. The study will utilize AI technology to correlate these markers with diagnostic and treatment plans. A total of 100 patients for each of the primary conditions and 80 healthy controls will be enrolled to gather comprehensive data for analysis.

Why it matters

Who can join: the full rules

1. Inclusion Criteria 1.1 A total of 100 patients with primary Parkinson's disease were enrolled. The inclusion criteria were as follows: patients with primary Parkinson's disease, based on the 2015 MDS diagnostic criteria for Parkinson's disease. Disorder (MMSE score \< 24); (3) those with severe mental illness who are difficult to cooperate.

   1.2 A total of 100 patients with Alzheimer's disease were enrolled. The inclusion criteria were as follows: patients with Alzheimer's disease, based on the IWG-2 clinical diagnostic criteria.

   1.3 Neurodegenerative diseases (non-PD and non-AD) group (n = 100) : meeting the diagnostic criteria of the corresponding diseases.

   1.4 Eighty healthy elderly controls were included. The inclusion criteria were as follows: ① voluntarily participated in this study and signed the informed consent; ② Age and gender were matched with the case group.

   1.5 80 young healthy controls, inclusion criteria: ① voluntarily participated in this study and signed the informed consent; ② Gender was matched with the case group, and the age was less than 60 years old.
2. Exclusion Criteria 2.1 A total of 100 patients with PD were enrolled. Exclusion criteria: ① patients with other central nervous system diseases, such as cerebrovascular diseases, brain trauma, inflammatory diseases of the central system, intracranial tumors and after neurosurgery; ② patients with various types of cognitive impairment (MMSE score \< 24); (3) those with severe mental illness who are difficult to cooperate.

2.2 A total of 100 patients with Alzheimer's disease were enrolled. The exclusion criteria were: ① patients with other central nervous system diseases, such as cerebrovascular diseases, brain trauma, central system inflammatory diseases, intracranial tumors and after neurosurgery; ② patients with severe mental illness who are difficult to cooperate.

2.3 Neurodegenerative diseases (non-PD non-AD) group (n = 100), exclusion criteria: ① patients with other central nervous system diseases, such as cerebrovascular diseases, brain trauma, central system inflammatory diseases, intracranial tumors and after neurosurgery; ② patients with severe mental illness who are difficult to cooperate.

2.4 Eighty healthy elderly controls were included. The exclusion criteria were as follows: ① History of chronic diseases related to the study subjects, such as cerebrovascular diseases, brain trauma, inflammatory diseases of the central system, intracranial tumors and neurosurgery; ② patients with various types of cognitive impairment (MMSE score \< 24); ③ Poor compliance.

2.5 80 young healthy controls, exclusion criteria: ① history of chronic diseases related to the study subjects, such as cerebrovascular diseases, brain trauma, inflammatory diseases of the central system, intracranial tumors and neurosurgical surgery; ② patients with various types of cognitive impairment (MMSE score \< 24); ③ Poor compliance.

Where it's running

• Qilu Hospital of Shandong University
  Jinan, Shandong, China Recruiting

Study contacts

• Study coordinator: Jun Ma
• Email: majun1228med@163.com
• Phone: 18560082039

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns

  This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.

  Recruiting University of Cambridge · Cambridge, CB2 · NCT07786116

• OCT in Neurological Practice: Use of Retinal Layers to Help Diagnose and Follow Neurological Diseases

  This study tests whether optical coherence tomography (OCT) of the retina can help in diagnosing and tracking multiple sclerosis, Alzheimer's, Parkinson's, migraines, and other headaches compared with healthy people.

  Recruiting IRCCS San Raffaele · Milan, Milano · NCT07720765

• Hyperspectral retinal imaging to detect Alzheimer’s and other neurodegenerative changes

  This project will test whether a special retinal camera that scans many wavelengths of light can detect signs of Alzheimer’s and other neurodegenerative diseases in people with dementia or at risk.

  Recruiting Center for Eye Research Australia · Melbourne, Victoria · NCT07545473

• Increasing daily physical activity to slow cognitive decline in alpha-synuclein disorders

  This study will test whether using a motivational smartphone app to increase everyday physical activity can help slow cognitive decline in people aged 50–80 with isolated REM sleep behavior disorder (an early sign of alpha‑synuclein disease).

  Recruiting University Hospital, Bonn · Bonn, North Rhine West-Falia · NCT07324330

• Omics-based profiling to find disease mechanisms and biomarkers in Alzheimer’s, Parkinson’s, FTD, and related dementias

  This project will use advanced omics tests (genetics, gene expression, proteins, and metabolites) to try to find biological markers and disease mechanisms in people with Alzheimer’s, Parkinson’s, frontotemporal and young-onset dementias, or mild cognitive impairment.

  Recruiting Ospedale Policlinico San Martino · Genoa, Genoa · NCT07235111

• Using ultra-high field and metabolic MRI to understand resilience and degeneration in the aging and diseased brain

  This project will try advanced 3T and 7T MRI scans, including sodium and phosphorus imaging, to see if metabolic and connectivity changes explain resilience and degeneration in adults with MS, NMOSD, MOGAD, Alzheimer’s, Parkinson’s, or healthy aging.

  Recruiting Assistance Publique Hopitaux De Marseille · Marseille · NCT07202494

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.